## **Tuberculosis profile**

## | High HIV burden

## Population 2012

## 3.8 million

|                               |                     | Rate                     |
|-------------------------------|---------------------|--------------------------|
| Estimates of TB burden * 2012 | Number (thousands)  | (per 100 000 population) |
| Mortality (excludes HIV+TB)   | 0.19 (0.18–0.19)    | 4.9 (4.8–5)              |
| Mortality (HIV+TB only)       | 0.037 (0.029-0.042) | 0.97 (0.77-1.1)          |
| Prevalence (includes HIV+TB)  | 2.4 (1.2–4.2)       | 64 (30–110)              |
| Incidence (includes HIV+TB)   | 1.8 (1.6–2)         | 48 (42–54)               |
| Incidence (HIV+TB only)       | 0.23 (0.2-0.26)     | 6.1 (5.3–6.8)            |
| Case detection, all forms (%) | 84 (75–95)          |                          |

| TB case notifications 2012 |       |      |                         |     |      |
|----------------------------|-------|------|-------------------------|-----|------|
| New cases                  |       | (%)  | Retreatment cases       |     | (%)  |
| Smear-positive             | 778   | (53) | Relapse                 | 60  | (28) |
| Smear-negative             | 288   | (20) | Treatment after failure | 6   | (3)  |
| Smear-unknown / not done   | 146   | (10) | Treatment after default | 42  | (20) |
| Extrapulmonary             | 248   | (17) | Other                   | 107 | (50) |
| Other                      | 0     | (0)  |                         |     |      |
| Total new                  | 1 460 |      | Total retreatment       | 215 |      |
| Other (history unknown)    | 0     |      |                         |     |      |

| Other (history unknown) | 0     |                      |       |
|-------------------------|-------|----------------------|-------|
| Total new and relapse   | 1 520 | Total cases notified | 1 675 |

| New cases | Smear-positive | Smear-negative/ unknown/<br>not done | Extrapulmonary |
|-----------|----------------|--------------------------------------|----------------|
| M:F ratio | 1.7            | 1.9                                  | 2.7            |
| Age < 15  | 28             | 107                                  | 29             |

| Laboratories   | 2012 |
|--|------|
| Smear (per 100 000 population)                         | 1.4  |
| Culture (per 5 million population)                     | 14.5 |
| Drug susceptibility testing (per 5 million population) | 1.3  |
| Is second-line drug susceptibility testing available?  | No   |


| Treatment success rate 2011 (%)            |    |                          |     |
|--|----|--------------------------|-----|
| New smear-positive and/or culture-positive | 84 | Is rifampicin used       |     |
| New smear-negative/extrapulmonary          | 76 | throughout treatment for |     |
| Retreatment                                | 59 | new patients?            | Yes |


| TB/HIV 2012   | Number | (%)  |
|---|--------|------|
| TB patients with known HIV status                                   | 1 600  | (96) |
| HIV-positive TB patients  | 224    | (14) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 200    | (89) |
| HIV-positive TB patients on antiretroviral therapy (ART)            | 145    | (65) |
| HIV-positive people screened for TB                                 |        |      |
| HIV-positive people provided with IPT                               |        |      |


| Estimates of MDR-TB burden 2012*               | New           | Retreatment |
|--|---------------|-------------|
| % of TB cases with MDR-TB                      | 2.2 (1.4–3.1) | 14 (4.6–23) |
| MDR-TB cases among notified pulmonary TB cases | 27 (17–38)    | 29 (10–49)  |


| Reported cases of MDR-TB 2012        | New     | Retreatment | Total |
|--------------------------------------|---------|-------------|-------|
| Cases tested for MDR-TB              | 2 (<1%) | 7 (3%)      | 11    |
| Laboratory-confirmed MDR-TB cases    | 2       | 7           | 11    |
| Patients started on MDR-TB treatment |         |             | 4     |

| Financing TB control                         | 2013 |
|--|------|
| National TB programme budget (US\$ millions) | 1.9  |
| % Funded domestically                        | 36%  |
| % Funded internationally                     | 24%  |
| % Unfunded                                   | 41%  |









New smear-positive and/or culture-positive New smear-negative/extrapulmonary Retreatment

